Rumpold H, Kraft D, Obexer G, Radaszkiewicz T, Majdic O, Bettelheim P, Knapp W, Böck G
Immunobiology. 1983 Feb;164(1):51-62. doi: 10.1016/S0171-2985(83)80017-5.
Four monoclonal antibodies VEP8, VEP9, VIM-D5, VIB-C5 against antigens expressed on human mature myeloid cells (polymorphonuclear leukocytes [PMNL] and/or monocytes) as well as on immature cells in the bone marrow were tested for reactivity with cell preparations highly enriched for large granular lymphocytes (LGL). These cells are known to be the main effector cells responsible for natural killer (NK) cell activity in human peripheral blood. Using indirect membrane immunofluorescence (IMF), none of these antibodies showed any reactivity at all. In addition, LGL-enriched cell preparations were tested with the anti-lymphocyte monoclonal antibodies OKT6, anti-Leu1, anti-Leu2a, anti-Leu3a, and anti-human Lyt3, and also with OKM1 antibody. Significant reactivity was found with anti-Leu2a (59 +/- 8%), anti-Lyt3 (55 +/- 4%) and OKM1 (81 +/- 11%) antibodies, whereas T6, Leu1, and Leu3a antigens were less pronounced or missing on LGL. As a further approach, another monoclonal antibody, VEP13, which reacts with LGL, granulocytes but not monocytes and is therefore different in its specificity from OKM1 and OKT10, was used for identification of LGL. The coexpression of antigens as defined by the above-mentioned antibodies and OKT10 on VEP13+ cells was studied. Again, phenotypes similar to those observed on LGL enriched by Percoll gradient centrifugation were found: of VEP13+ cells 84 +/- 6% reacted with OKM1, 82 +/- 5% with OKT10, 52 +/- 17% with anti-human Lyt3, and 48 +/- 14% with anti-Leu2a, whereas VEP8, VEP9, VIM-D5, VIB-C5, T6, Leu1, Leu3a antigens were not expressed on VEP13+ cells. Taken together as an overall evaluation of phenotypic characteristics, our data indicate that LGL cannot be integrated into one of the known lymphocytic or myelomonocytic lineages. LGL show an intermediate phenotype depending possibly on varying differentiation or activation stages of haemopoietic cells. However, the possibility also exists that LGL belong to a separate, yet undefined cell lineage.
针对人类成熟髓细胞(多形核白细胞[PMNL]和/或单核细胞)以及骨髓中未成熟细胞上表达的抗原的四种单克隆抗体VEP8、VEP9、VIM-D5、VIB-C5,被检测与高度富集大颗粒淋巴细胞(LGL)的细胞制剂的反应性。已知这些细胞是人类外周血中负责自然杀伤(NK)细胞活性的主要效应细胞。使用间接膜免疫荧光(IMF),这些抗体均未显示出任何反应性。此外,用抗淋巴细胞单克隆抗体OKT6、抗-Leu1、抗-Leu2a、抗-Leu3a和抗人Lyt3以及OKM1抗体检测富集LGL的细胞制剂。发现抗-Leu2a(59±8%)、抗-Lyt3(55±4%)和OKM1(81±11%)抗体有显著反应性,而T6、Leu1和Leu3a抗原在LGL上表达较弱或缺失。作为进一步的方法,另一种与LGL、粒细胞反应但不与单核细胞反应,因此其特异性不同于OKM1和OKT10的单克隆抗体VEP13,被用于鉴定LGL。研究了上述抗体和OKT10所定义的抗原在VEP13+细胞上的共表达。同样,发现与通过Percoll梯度离心富集的LGL上观察到的表型相似:VEP13+细胞中84±6%与OKM1反应,82±5%与OKT10反应,52±17%与抗人Lyt3反应,48±14%与抗-Leu2a反应,而VEP8、VEP9、VIM-D5、VIB-C5、T6、Leu1、Leu3a抗原在VEP13+细胞上不表达。综合作为对表型特征的总体评估,我们的数据表明LGL不能归入已知的淋巴细胞或髓单核细胞谱系之一。LGL表现出中间表型,可能取决于造血细胞的不同分化或激活阶段。然而,LGL也有可能属于一个单独的、尚未明确的细胞谱系。